|
?:authorAffiliation
|
-
[\'Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139.\', \'The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.\', \'Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.\', \'Ragon Institute of Massachusetts General Hospital (MGH), MIT, Harvard, Cambridge, MA 02139.\', \'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115.\', \'Department of Pharmaceutical Chemistry, Vaccine Analytics, and Formulation Center, University of Kansas, Lawrence, KS 66047.\', \'Department of Biochemistry, University of Washington, Seattle, WA 98195.\', \'Institute for Protein Design, University of Washington, Seattle, WA 98195.\', \'Vaccine Formulation Institute, 1228 Plan-Les-Ouates, Geneva, Switzerland.\', \'Harvard-MIT Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139.\', \'Bioqual, Inc., Rockville, MD 20850.\', \'Bill & Melinda Gates Medical Research Institute, Cambridge, MA 02139.\', \'Bill & Melinda Gates Foundation, Seattle, WA 98109.\', \'Massachusetts Consortium on Pathogen Readiness, Boston, MA 02115.\', \'Howard Hughes Medical Institute, Chevy Chase, MD 20815.\', \'Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139; clove@mit.edu.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}